DUBLIN--(BUSINESS WIRE)--The "Orphan Drug Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.
The orphan drug market is projected to grow at a CAGR of 10.94% to reach US$285.799 billion in 2023 from US$153.275 billion in 2017.
During the forecast period, prescription sales in the orphan drug sector are projected to grow at twice the rate of the overall prescription market.
However, various government authorities encourage to develop and market orphan drugs. The cost incurred during the research and development of orphan drugs is higher when compared with non-orphan drugs.
The orphan drug market is classified into various segments by disease types, indication, and geographical regions.
The oncologic segment of the orphan drug market was the most dominant sector due to a large number of rare cancer form cases found in patients. Oncology segment is expected to maintain the trend and will be the key segment during the period of the next five years.
The global orphan drug market is expanding globally to cure rare diseases and thus expected to grow in all regions. North America is estimated to have a significant market share due to the high number of research and development going on in the region coupled with high medical cost and skilled labor force available in the region.
Key Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Orphan Drug Market by Disease Type
6. Orphan Drug Market by Product Type
7. Orphan Drug Market by Geography
8. Competitive Intelligence
9. Company Profiles
- Bayer
- Amryt Pharma PLC
- Brisol-Myers Squibb Company
- Novartis AG
- Celgene Corporation
- F.Hoffman-La Roche AG
- Pfizer Inc.
- Alexion
- Sanofi
- AbbVie, Inc.
- RegeneRX Biopharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- Shire PLC
- Merck & Co. Inc.
For more information about this report visit https://www.researchandmarkets.com/research/fk3mx4/the_global_orphan?w=4
